Log in

Relevant bibliographies by topics / Treatment resistance depression / Journal articles

To see the other types of publications on this topic, follow the link: Treatment resistance depression.

Journal articles on the topic 'Treatment resistance depression'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Treatment resistance depression.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kasper, S. "Treatment Resistance in Depression." European Psychiatry 26, S2 (2011): 2022. http://dx.doi.org/10.1016/s0924-9338(11)73725-7.

Full text

Abstract:

Due to the advancement of antidepressant medication, more patients receive treatment in everyday practice, and response/remission is not achieved in the majority of the patients. Several attempts to validate the definition of treatment resistance have been undertaken and the criteria usually encompased to treatment sequences are that two different classes of antidepressants given in a sufficient dosage for a sufficient time have to be administered. Clinically, it is evident that this defintion does not include the treatment refractory patients which could be defined as not responding to numeru

APA, Harvard, Vancouver, ISO, and other styles

2

Karstensen, Valerie, Geoffrey Olsen, and Mathias Bastholm. "Understanding Treatment Resistance in Depression." KMAN Counseling and Psychology Nexus 2, no. 1 (2024): 63–69. https://doi.org/10.61838/kman.psynexus.2.1.10.

Full text

Abstract:

Treatment-resistant depression (TRD) represents a significant challenge in psychiatric care, affecting a substantial portion of patients who do not respond to conventional treatment modalities. This qualitative study aims to explore the lived experiences of individuals diagnosed with TRD to better understand the personal, social, and systemic factors that contribute to treatment resistance and identify potential avenues for more effective interventions. The study utilized a qualitative design, conducting semi-structured interviews with 33 participants diagnosed with TRD. Data collection contin

APA, Harvard, Vancouver, ISO, and other styles

3

Karstensen, Valerie, Geoffrey Olsen, and Mathias Bastholm. "Understanding Treatment Resistance in Depression." KMAN Counseling and Psychology Nexus 2, no. 1 (2024): 63–69. http://dx.doi.org/10.61838/kman.psychnexus.2.1.10.

Full text

Abstract:

Treatment-resistant depression (TRD) represents a significant challenge in psychiatric care, affecting a substantial portion of patients who do not respond to conventional treatment modalities. This qualitative study aims to explore the lived experiences of individuals diagnosed with TRD to better understand the personal, social, and systemic factors that contribute to treatment resistance and identify potential avenues for more effective interventions. The study utilized a qualitative design, conducting semi-structured interviews with 33 participants diagnosed with TRD. Data collection contin

APA, Harvard, Vancouver, ISO, and other styles

4

Cuijpers, Pim. "From treatment resistance to sequential treatments of depression." World Psychiatry 22, no. 3 (2023): 418–19. http://dx.doi.org/10.1002/wps.21138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chaturvedi, Santosh K. "Treatment Resistance and Chronicity of Depression." Canadian Journal of Psychiatry 34, no. 5 (1989): 477. http://dx.doi.org/10.1177/070674378903400529.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Millet, E., R. Icick, and J. P. Lépine. "Treatment-resistant depression: From pseudo-resistance to full resistance." European Psychiatry 26, S2 (2011): 638. http://dx.doi.org/10.1016/s0924-9338(11)72344-6.

Full text

Abstract:

IntroductionTreatment-resistant depression (TRD) has been a controversial issue for more than 35 years. Despite a large number of publications, clinicians and researchers still know few about the prevalence of TRD since no staging method has been validated.ObjectivesWe sought to assess similarities and differences between the 4 TRD-staging methods published to date and assess TRD prevalence in a clinical sample. We also wanted to look for clinical factors associated with TRD.MethodsWe conducted a clinical study in a psychiatric unit of a university hospital. We designed a hetero-questionnaire

APA, Harvard, Vancouver, ISO, and other styles

7

Kelly, Cristina Nunes Silva, and Gisele Santos Maria. "Physiological benefits of resistance training in depressive persons: a literature review." International Journal of Medical Reviews and Case Reports 3, no. 4 (2019): 160–66. https://doi.org/10.5455/IJMRCR.PHYSIOLOGICALBENEFITS-OF-RESISTANCE-TRAINING.

Full text

Abstract:

The current society, due to the technological advance, excessive collections, reigning individualism, among others, is faced with a significant increase of individuals with depression. Some authors conceptualize depression as a disease where the individual feels inferior to everything and everyone, with no capacity and willingness to face the challenges, because it presents a feeling of fear of failure, thus promoting a reduction of the feeling of pleasure, irritability, feelings of guilt and, in more serious cases, suicidal thoughts.The concept of depression is applied to a mood disorder, enc

APA, Harvard, Vancouver, ISO, and other styles

8

Rihmer, Z. "Treatment resistance in bipolar disorder." European Psychiatry 26, S2 (2011): 2025. http://dx.doi.org/10.1016/s0924-9338(11)73728-2.

Full text

Abstract:

Antidepressant-resistant major depression (AD-RD) is a great challenge for the treating clinician. The most widely accepted definition of AD-RD refers that the depressed patient does not show a clinically significant response after at least two adequate trials of different classes of antidepressants. In spite of the fact that there are several causes of AD-RD in general, there is increasing evidence that one of the most common sources of it is the unrecognized bipolar nature of the “unipolar” major depressive episode, when the patients receive antidepressant monotherapy - unprotected by mood s

APA, Harvard, Vancouver, ISO, and other styles

9

Yunilayne, O. A., E. G. Starostina, and I. V. Oleichik. "Hypothalamo-Pituitary-Adrenal Axis in Depressive Disorders and Treatment Resistance." Psikhiatriya 21, no. 1 (2023): 73–90. http://dx.doi.org/10.30629/2618-6667-2023-21-1-73-90.

Full text

Abstract:

Background: hypothalamo-pituitary-adrenal (HPA) axis plays an important role in the pathogenesis of depression. Patterns of HPA functioning depend on both biologic factors and psychological background, which, taken together, may increase the risk of depression later on. Objective: to analyze scientific publications on pathophysiology of depression, linked to HPA disruption, assess causal relationship between hypercorticism and depression, role of hypercorticism in clinical symptoms and course of depressive disorder.Material and methods: according to the key words “hypercortiсism”, “depression

APA, Harvard, Vancouver, ISO, and other styles

10

Khaustova, Olena. "Resistant depression: criteria for determination, risk factors and therapeutic strategies." Psychosomatic Medicine and General Practice 2, no. 3 (2017): 020338. http://dx.doi.org/10.26766/pmgp.v2i3.38.

Full text

Abstract:

Background Therapy of resistant depression raises a number of diagnostic and therapeutic problems, requires the solution of a number of methodological issues. A scientific discussion continues around the definition of depression resistance, assessment of the degree of reduction of depressive symptoms, the level of social and role functioning of patients; the improvement of models for determining the degree of resistance to various types of depression therapy continues; new methods of therapy and new algorithms of combined therapy are being developed. The ultimate goal of all these efforts shou

APA, Harvard, Vancouver, ISO, and other styles

11

Cristianne, Confessor Castilho Lopes, Ohana Marques Azzini Vitor, Barbosa Lopes Eduardo, et al. "Use of Esketamine in the Treatment of Depression: A Systematic Review of Clinical Evidence." International Journal of Medical Science and Clinical Research Studies 04, no. 11 (2024): 2042–49. https://doi.org/10.5281/zenodo.14167056.

Full text

Abstract:

<strong>Introduction: </strong>Depression is a highly prevalent psychiatric condition and considered one of the leading causes of disability worldwide, affecting millions of individuals across different age groups and social contexts. Esketamine, a ketamine derivative, has emerged as a promising option for the treatment of resistant depression.   <strong>Objective: </strong>To synthesize the available evidence on the use of esketamine in depressed patients, focusing on its efficacy, safety, and possible limitations.     <strong>Methods: </strong>This study is a sy

APA, Harvard, Vancouver, ISO, and other styles

12

Singh, Vijender, and Bhavuk Garg. "Insulin resistance and depression: Relationship and treatment implications." Journal of Mental Health and Human Behaviour 24, no. 1 (2019): 4. http://dx.doi.org/10.4103/jmhhb.jmhhb_55_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Halaris, A., N. Alvi, E. Meresh, and A. Sharma. "Inflammation control reverses treatment-resistance in bipolar depression." Neurology, Psychiatry and Brain Research 20, no. 1 (2014): 12–13. http://dx.doi.org/10.1016/j.npbr.2014.01.151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Koplewicz, Harold S. "Misguided Resistance to Appropriate Treatment for Adolescent Depression." Journal of Child and Adolescent Psychopharmacology 14, no. 1 (2004): 7. http://dx.doi.org/10.1089/104454604773840391.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Dinan, Ted. "Treatment approaches to therapy-resistant depression." Journal of Psychopharmacology 9, no. 2_suppl (1995): 199–204. http://dx.doi.org/10.1177/0269881195009002051.

Full text

Abstract:

Resistance to antidepressant treatment is a controversial field and therapy resistance has received a wide range of definitions. The field has suffered from a lack of consensus on how to classify treatment resistance and from the related failure to standardise clinical criteria in trials of new therapeutic approaches. A significant proportion of tricyclic antidepressant (TCA)-resistant depression results from the failure to sustain an adequate course of therapy. This can be due to either inadequate prescribing or the poor tolerability of TCAs. The majority of cases of treatment resistance, how

APA, Harvard, Vancouver, ISO, and other styles

16

Flint, Alastair J. "Treatment-resistant Depression in Late Life." CNS Spectrums 7, no. 10 (2002): 733–38. http://dx.doi.org/10.1017/s1092852900008725.

Full text

Abstract:

ABSTRACTTreatment resistance is reported in up to 40% of older patients with major depression. Before labeling an episode of depression as treatment resistant, it is important to ensure that the diagnosis is correct and that the patient has received and adhered to an adequate dose of treatment for an appropriate length of time. It is also important to assess the patient for comorbid physical and psychiatric conditions that can contribute to treatment resistance. In patients who do not experience remission of symptoms with an adequate trial of medication, the following options can be considered

APA, Harvard, Vancouver, ISO, and other styles

17

Rasgon, N., B. McEwen, and K. W. Lin. "Insulin Resistance and Telomere Length in Treatment of Depressive Disorders." European Psychiatry 41, S1 (2017): S61—S62. http://dx.doi.org/10.1016/j.eurpsy.2017.01.052.

Full text

Abstract:

Insulin resistance and markers of Allostatic load in depressionIntroductionAmong patients with major depression, increased inflammatory markers at baseline may predict an anti-depressant response. Reducing inflammation may augment response to psychotropic medications. Few studies have investigated an association between Leukocyte Telomere Length (LTL) and therapeutic response in depression, reporting mixed results. No studies assessed LTL and treatment response with PPAR-γ agonists.Objectives(1) LTL as a predictor of anti-depressant response to PPAR-γ agonist in patients with unremitted depres

APA, Harvard, Vancouver, ISO, and other styles

18

Fekadu, Abebaw, Sarah Wooderson, Catherine Donaldson, et al. "A Multidimensional Tool to Quantify Treatment Resistance in Depression." Journal of Clinical Psychiatry 70, no. 2 (2009): 177–84. http://dx.doi.org/10.4088/jcp.08m04309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bonner, Deirdre, and Robert Howard. "Treatment-Resistant Depression in the Elderly." International Psychogeriatrics 7, S1 (1995): 83–94. http://dx.doi.org/10.1017/s1041610295002377.

Full text

Abstract:

Apparent treatment-resistant depression (TRD) is frequently encountered by and poses particular challenges for the old-age psychiatrist. The prevalence of true nonresponse to treatment is not known with accuracy but reports put it at 18% to 40% for the elderly. This article reviews the concept of TRD in the elderly, discussing the factors involved in apparent resistance and the treatment of this group. We suggest that absolute TRD may be a rarer entity than the estimated 18% to 40% if depressed patients are treated carefully and vigorously.

APA, Harvard, Vancouver, ISO, and other styles

20

Lipsman, Nir, Roger S. McIntyre, Peter Giacobbe, Cristina Torres, Sidney H. Kennedy, and Andres M. Lozano. "Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets." Bipolar Disorders 12, no. 7 (2010): 691–701. http://dx.doi.org/10.1111/j.1399-5618.2010.00868.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Strawn, Jeffrey R., Scott T. Aaronson, Ahmed Z. Elmaadawi, et al. "Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance." Journal of Child and Adolescent Psychopharmacology 30, no. 4 (2020): 261–66. http://dx.doi.org/10.1089/cap.2020.0008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Mitchell, Philip. "The Pharmacological Treatment of Tricyclic-Resistant Depression: Review and Management Guidelines." Australian & New Zealand Journal of Psychiatry 21, no. 4 (1987): 442–51. http://dx.doi.org/10.3109/00048678709158911.

Full text

Abstract:

Despite the introduction of a wide range of antidepressant drugs since the late 1950s, approximately 30–50% of depressed subjects do not respond to these agents. Various treatment strategies, both pharmacological and non-pharmacological, have been proposed for treatment-resistant depression. This paper critically reviews the studies of single and combined pharmacological treatments for tricyclic-resistant patients, with a particular discussion of lithium augmentation. The major inadequacies of these studies have been the frequent lack of definitions of treatment resistance, the heterogeneity o

APA, Harvard, Vancouver, ISO, and other styles

23

Gonda, X. "Reconceptualising depression along the endogeneus-reactive spectrum: are different genes involved in depression depending on presence vs absence of exposure to stress?" European Psychiatry 67, S1 (2024): S26. http://dx.doi.org/10.1192/j.eurpsy.2024.99.

Full text

Abstract:

Abstract Depression is a complex and highly heterogeneous disorder with an omnigenic and multifactorial background. This diversity is obvious not only in its symptomatic manifestation but also in its neurobiological underpinnings which is one potential factor contributing to the high observed rate of treatment resistance. Thus, subtyping depressions, understanding their distinct neurobiological and genetic background, and potentially developing biomarkers aiding their differential diagnosis may bring us one step closer to more effective treatment. The present talk will overview the different e

APA, Harvard, Vancouver, ISO, and other styles

24

Ozminkowski, RJ, JM Russell, WH Crown, et al. "PMH23 THE COST CONSEQUENCES OF CONTINUED TREATMENT-RESISTANCE IN DEPRESSION." Value in Health 5, no. 3 (2002): 235. http://dx.doi.org/10.1016/s1098-3015(10)61088-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sauvaget, A. "Cost-utility of tDCS in depression treatment." European Psychiatry 66, S1 (2023): S45. http://dx.doi.org/10.1192/j.eurpsy.2023.166.

Full text

Abstract:

AbstractDepression is one of the most common psychiatric disorders causing considerable economic burden. However, the current treatment as usual, pharmacotherapy and psychotherapy, provides unsatisfactory treatment outcome for majority of the patients and in most cases fails to prevent treatment resistance and chronicity. tDCS, has emerged as a new neuromodulation treatment and has shown efficacy in depressed patients. To provide important insight to the payers, the cost-utility of tDCS in comparison to treatment as usual, should be clarified.Disclosure of InterestNone Declared

APA, Harvard, Vancouver, ISO, and other styles

26

Macewan, G. William, and Ronald A. Remick. "Treatment Resistant Depression: A Clinical Perspective*." Canadian Journal of Psychiatry 33, no. 9 (1988): 788–92. http://dx.doi.org/10.1177/070674378803300902.

Full text

Abstract:

One hundred and fourteen patients with a diagnosis of “treatment resistant depression” (TRD) were assessed and treated at a Mood Disorders Clinic. Diagnostically, 52 (45.6%) subjects met criteria for bipolar disorder, 49 (42.9%) for recurrent depression, and 13 (11.4%) patients did not fulfill diagnostic criteria for affective disorder which explained their treatment resistance. With appropriate, individualized treatment, 59 of 98 (60.2%) patients had complete symptom remission based on clinical and psychometric ratings (initial Ham-D 26.7, final Ham-D 5.9). Eighteen of 98 patients had partial

APA, Harvard, Vancouver, ISO, and other styles

27

Thase, M. "C.01.02 Disease severity and treatment-resistance: unraveling the treatment options in depression." European Neuropsychopharmacology 20 (August 2010): S637. http://dx.doi.org/10.1016/s0924-977x(10)70979-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Nelsen, Michael R., and David L. Dunner. "Treatment Resistance in Unipolar Depression and Other Disorders: Diagnostic Concerns and Treatment Possibilities." Psychiatric Clinics of North America 16, no. 3 (1993): 541–66. http://dx.doi.org/10.1016/s0193-953x(18)30164-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Khantakova, Julia N., Anastasia Mutovina, Kseniya A. Ayriyants, and Natalia P. Bondar. "Th17 Cells, Glucocorticoid Resistance, and Depression." Cells 12, no. 23 (2023): 2749. http://dx.doi.org/10.3390/cells12232749.

Full text

Abstract:

Depression is a severe mental disorder that disrupts mood and social behavior and is one of the most common neuropsychological symptoms of other somatic diseases. During the study of the disease, a number of theories were put forward (monoamine, inflammatory, vascular theories, etc.), but none of those theories fully explain the pathogenesis of the disease. Steroid resistance is a characteristic feature of depression and can affect not only brain cells but also immune cells. T-helper cells 17 type (Th17) are known for their resistance to the inhibitory effects of glucocorticoids. Unlike the in

APA, Harvard, Vancouver, ISO, and other styles

30

Rasgon, Natalie L., Heather A. Kenna, Katherine E. Williams, Bevin Powers, Tonita Wroolie, and Alan F. Schatzberg. "Rosiglitazone Add-On in Treatment of Depressed Patients with Insulin Resistance: a Pilot Study." Scientific World JOURNAL 10 (2010): 321–28. http://dx.doi.org/10.1100/tsw.2010.32.

Full text

Abstract:

A number of cross-sectional studies have suggested an association between insulin resistance (IR) and affective disorders. However, limited data exist on potential changes in IR in a prospective treatment of depression. The present pilot study tested the hypothesis that improvement of IR with the addition of an insulin-sensitizing agent would improve mood in nondiabetic patients with unipolar or bipolar depression, who had surrogate blood markers suggestive of IR. Surrogate IR-criteria blood markers were fasting plasma glucose >100 mg/dl or triglyceride (TG) to high density lipoprotein (HDL

APA, Harvard, Vancouver, ISO, and other styles

31

José, Cruz, Reyes Lua, Zan Wang, Cruz Iván, and Bossano Fernando. "iTBS combined with Cognitive Behavioral Therapy for treatment resistance depression (TRD)." Brain Stimulation 14, no. 5 (2021): 1407. http://dx.doi.org/10.1016/j.brs.2021.07.032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Little, John T., Charles F. Reynolds, Mary Amanda Dew, et al. "How Common Is Resistance to Treatment in Recurrent, Nonpsychotic Geriatric Depression?" American Journal of Psychiatry 155, no. 8 (1998): 1035–38. http://dx.doi.org/10.1176/ajp.155.8.1035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Vadodaria, Krishna C., Yuan Ji, Michelle Skime, et al. "Studying treatment resistance in depression using patient derived neurons in vitro." Molecular Psychiatry 24, no. 6 (2019): 775. http://dx.doi.org/10.1038/s41380-019-0424-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Gibson, TB, Y. Jing, GS Carls, et al. "PMH26 THE COST BURDEN OF TREATMENT RESISTANCE IN PATIENTS WITH DEPRESSION." Value in Health 12, no. 3 (2009): A177. http://dx.doi.org/10.1016/s1098-3015(10)73947-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Dudek, Dominika, Janusz K. Rybakowski, Marcin Siwek, et al. "Risk factors of treatment resistance in major depression: Association with bipolarity." Journal of Affective Disorders 126, no. 1-2 (2010): 268–71. http://dx.doi.org/10.1016/j.jad.2010.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Miller, A. H. "211. Inflammation and treatment resistance in major depression: A perfect storm." Brain, Behavior, and Immunity 25 (August 2011): S239—S240. http://dx.doi.org/10.1016/j.bbi.2011.07.214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bennabi, D., B. Aouizerate, W. El-Hage, et al. "Risk factors for treatment resistance in unipolar depression: A systematic review." Journal of Affective Disorders 171 (January 2015): 137–41. http://dx.doi.org/10.1016/j.jad.2014.09.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Poirier, M. F., and P. Boyer. "Venlafaxine and paroxetine in treatment-resistant depression." British Journal of Psychiatry 175, no. 1 (1999): 12–16. http://dx.doi.org/10.1192/bjp.175.1.12.

Full text

Abstract:

BackgroundAbout one-third of patients fail to respond to initial antidepressant therapy, which suggests a need for more effective drugs.AimsTo compare the efficacy and safety of venlafaxine and paroxetine in 122 patients with non-chronic treatment-resistant depression.MethodIn-patients or out-patients satisfying DSM – III – R criteria for major depression in evolution for less than eight months, having a baseline HAM–D score 18 and a HAM – D Item 3 score < 3 were eligible. Patients were required to have a history of resistance to two previous antidepressant treatments and a CGI improvement

APA, Harvard, Vancouver, ISO, and other styles

39

Francis, Linus, and Davis Manuel. "Anxiety and Depression in School-going children with Epilepsy." Annals of International Medical and Dental Research 8, no. 1 (2022): 93–97. http://dx.doi.org/10.53339/aimdr.2022.8.1.13.

Full text

Abstract:

Background: This study was designed to find the prevalence of anxiety and depression in school-going children with epilepsy.Methods:All the patients with epilepsy presenting during the study period underwent detailed clinical and EEG evaluation. Hospital Anxiety and Depression score (HADS) was used to screen for anxiety and depression.Results:We identified 190 patients with epilepsy during the study period. Out of these 30 (15.8%) were diagnosed as having treatment resistance epilepsy. Anxiety was diagnosed in 114 (60%) and depression in 62 (32.6%). Patients with drug resistant epilepsy were f

APA, Harvard, Vancouver, ISO, and other styles

40

Wilkowska, Alina, and Wiesław Jerzy Cubała. "The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine." International Journal of Molecular Sciences 23, no. 23 (2022): 14605. http://dx.doi.org/10.3390/ijms232314605.

Full text

Abstract:

Treatment-resistant depression is a pleomorphic phenomenon occurring in 30% of patients with depression. The chance to achieve remission decreases with every subsequent episode. It constitutes a significant part of the global disease burden, causes increased morbidity and mortality, and is associated with poor quality of life. It involves multiple difficult-to-treat episodes, with increasing resistance over time. The concept of staging captures the process of changes causing increasing treatment resistance and global worsening of functioning in all areas of life. Ketamine is a novel rapid-acti

APA, Harvard, Vancouver, ISO, and other styles

41

Serra-Blasco, Maria, Maria J. Portella, Beatriz Gómez-Ansón, et al. "Effects of illness duration and treatment resistance on grey matter abnormalities in majordepression." British Journal of Psychiatry 202, no. 6 (2013): 434–40. http://dx.doi.org/10.1192/bjp.bp.112.116228.

Full text

Abstract:

BackgroundFindings of brain structural changes in major depressive disorder are still inconsistent, partly because some crucial clinical variables have not been taken into account.AimsTo investigate the effect of major depressive disorder on grey matter volumes.MethodVoxel-based morphometry was used to compare 66 patients with depression at different illness stages (22 each with first-episode, remitted-recurrent and treatment resistant/chronic depression) with 32 healthy controls. Brain volumes were correlated with clinical variables.ResultsVoxel-based morphometry showed a significant group ef

APA, Harvard, Vancouver, ISO, and other styles

42

Kiebs, Maximilian, René Hurlemann, and Julian Mutz. "Repetitive transcranial magnetic stimulation in non-treatment-resistant depression." British Journal of Psychiatry 215, no. 2 (2019): 445–46. http://dx.doi.org/10.1192/bjp.2019.75.

Full text

Abstract:

SummaryRepetitive transcranial magnetic stimulation (rTMS) has been investigated as treatment for major depressive episodes since the early 1990s. Using data from a recent meta-analysis, we show that most patients included in randomised trials display relatively high degrees of treatment resistance. This might have unfavourably biased the clinical reputation of rTMS.Declaration of interestsM.K. has received a lecture fee from Innomed Medizintechnik in 2017 and 2018.

APA, Harvard, Vancouver, ISO, and other styles

43

Beer, Cristina, Fiona Rae, Annalese Semmler, and Joanne Voisey. "Biomarkers in the Diagnosis and Prediction of Medication Response in Depression and the Role of Nutraceuticals." International Journal of Molecular Sciences 25, no. 14 (2024): 7992. http://dx.doi.org/10.3390/ijms25147992.

Full text

Abstract:

Depression continues to be a significant and growing public health concern. In clinical practice, it involves a clinical diagnosis. There is currently no defined or agreed upon biomarker/s for depression that can be readily tested. A biomarker is defined as a biological indicator of normal physiological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention that can be objectively measured and evaluated. Thus, as there is no such marker for depression, there is no objective measure of depression in clinical practice. The discovery of such a biomarker/s woul

APA, Harvard, Vancouver, ISO, and other styles

44

Halaris, Angelos, Emilie Sohl, and Elizabeth A. Whitham. "Treatment-Resistant Depression Revisited: A Glimmer of Hope." Journal of Personalized Medicine 11, no. 2 (2021): 155. http://dx.doi.org/10.3390/jpm11020155.

Full text

Abstract:

Major Depressive Disorder (MDD) is a highly prevalent psychiatric disorder worldwide. It causes individual suffering, loss of productivity, increased health care costs and high suicide risk. Current pharmacologic interventions fail to produce at least partial response to approximately one third of these patients, and remission is obtained in approximately 30% of patients. This is known as Treatment-Resistant Depression (TRD). The burden of TRD exponentially increases the longer it persists, with a higher risk of impaired functional and social functioning, vast losses in quality of life and sig

APA, Harvard, Vancouver, ISO, and other styles

45

Asadi, M., and S. Mahdavi. "Transcranial direct current stimulation in treatment – resistance unipolar major depressive disorder." European Psychiatry 33, S1 (2016): S95. http://dx.doi.org/10.1016/j.eurpsy.2016.01.064.

Full text

Abstract:

ObjectiveMDD is a common, chronic and recurrent illness .it is essential to reach full remission in acute treatment. tDCS is a non-invasive brain stimulation that uses direct electrical currents to stimulate specific parts of the brain.AimIs to assess the effectiveness of tDCS in patients with treatment resistance MDD.MethodEighty outpatients of a psychiatric clinic were selected. Subjects meet (DSM-IV) diagnostic criteria for MDD. All patients had failed to respond to at least two standard antidepressant medication, in the current episode. Patients with bipolar depressive disorder, MDD with p

APA, Harvard, Vancouver, ISO, and other styles

46

Knopf, Alison. "New concept: Treatment‐refractory addiction." Alcoholism & Drug Abuse Weekly 36, no. 33 (2024): 1–3. http://dx.doi.org/10.1002/adaw.34227.

Full text

Abstract:

The last issue of August is sometimes quiet; lots of vacations, little of note in the news. This year, the Journal of Addiction Medicine came to the rescue with bold commentaries from top experts in the field introducing new concepts: specifically, “treatment‐refractory addiction.” The commentaries also play into a rich literature of treatment resistance in general, starting with depression.

APA, Harvard, Vancouver, ISO, and other styles

47

KIrlI-, E., T. D. Berkol, G. Sarıdogan, and H. Erensoy. "Detection of perceptions and thoughts that may lead to disruption of insulin use in type 2 diabetes mellitus patients." European Psychiatry 33, S1 (2016): S397. http://dx.doi.org/10.1016/j.eurpsy.2016.01.1426.

Full text

Abstract:

AimIn this study we aimed to identify the perceptions and thoughts and their association with state/trait anxiety, depression that may lead to resistance to insulin treatment in patients with previously diagnosed type 2 diabetes mellitus (DM) patients in order to facilitate their compliance with insulin treatment.MethodIn this study, 120 patients were recruited with a previous type 2 DM diagnosis from the diabetes outpatient clinic. Patients were evaluated with sociodemographic data, State-Trait Anxiety Inventory, Problem Areas in Diabetes Scale, Insulin Treatment Appraisal Scale, Beck Depress

APA, Harvard, Vancouver, ISO, and other styles

48

Quaglia, Federico Carlos Augusto. "FC21: Clinical and therapeutic challenges in Geriatric Depression and Sleep Apnea Hypopnea Syndrome." International Psychogeriatrics 36, S1 (2024): 51. http://dx.doi.org/10.1017/s1041610224001431.

Full text

Abstract:

Objectives: Health professionals in our setting rarely ask adequately about sleep disorders beyond insomnia in depressive patients. This presentation aims to review the possible clinical situations between geriatric depression (GD) and sleep apnea and hypopnea syndrome (SAHS) and highlight the clinical impact of their adequate detection and treatment.Methods: Presentation of a sample of 25 older adult patients from the Geriatric Neuropsychiatry Clinic and the Psychogeriatric Section of the Department of Psychiatry of the CEMIC (Buenos Aires, Argentina) with diagnoses of GD and SAHS.Results: Pr

APA, Harvard, Vancouver, ISO, and other styles

49

Avanoğlu, K. B., N. Oktar Erdoğan, E. Ağaoğlu, and K. Başar. "Comparison of Staging Methods for Treatment-Resistant Depression: Chart Review." European Psychiatry 67, S1 (2024): S255—S256. http://dx.doi.org/10.1192/j.eurpsy.2024.540.

Full text

Abstract:

IntroductionTreatment-resistant depression (TRD) lacks a universally consistent definition due to varied interpretations despite attempts to define it based on inadequate response or remission despite sufficient antidepressant treatment. There’s a crucial demand for a uniform definition and staging to streamline its effective management amid diverse treatment options and the complex nature of resistance. Five methods have emerged to define and classify treatment resistance reliably.Objectives The aim of this study is to compare the five staging methods (Thase&Rush SM (T&R), European St

APA, Harvard, Vancouver, ISO, and other styles

50

Castello, Juan Pablo, Marco Pasi, Patryk Kubiszewski, et al. "Cerebral Small Vessel Disease and Depression Among Intracerebral Hemorrhage Survivors." Stroke 53, no. 2 (2022): 523–31. http://dx.doi.org/10.1161/strokeaha.121.035488.

Full text

Abstract:

Background and Purpose: Intracerebral hemorrhage (ICH) is an acute manifestation of cerebral small vessel disease (CSVD), usually cerebral amyloid angiopathy or hypertensive arteriopathy. CSVD-related imaging findings are associated with increased depression incidence in the general population. Neuroimaging may, therefore, provide insight on depression risk among ICH survivors. We sought to determine whether CSVD CT and magnetic resonance imaging markers are associated with depression risk (before and after ICH), depression remission, and effectiveness of antidepressant treatment. Methods: We

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!